Skip to main content
HUM
NYSE Finance

Humana Q2 Earnings: Membership Surge Fuels Revenue, but Benefit Ratio Edges Up

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Neutral
Importance info
8
Price
$360.92
Mkt Cap
$43.333B
52W Low
$163.11
52W High
$428.882
52W Position info
121% above low
Off High info
16% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

HUM has more than doubled off its 52-week low of $163.11.

Summary

Humana reported Q2 adjusted EPS of $7.61, beating estimates, with revenue up 26% on massive Medicare membership growth. The benefit ratio rose to 91.1%, and the company affirmed its full-year adjusted EPS guidance of at least $9.


Key Events · Earnings and Guidance · HUM

  • Q2 Earnings Beat

    Adjusted EPS of $7.61 exceeded the $9 full-year floor, with GAAP net income of $694M ($5.73 diluted EPS) vs $545M a year ago.

  • Membership Surge

    Individual Medicare Advantage membership grew 23.4% YoY to 6.45M; stand-alone PDP membership jumped 62.6% to 3.95M, driving a 26% revenue increase.

  • Benefit Ratio Pressure

    Consolidated benefit ratio rose to 91.1% from 89.7%, reflecting new member onboarding costs and lower favorable prior-year reserve development ($53M vs $161M).

  • Transformation Charges

    Value creation initiative charges of $56M in Q2 (vs $29M a year ago) as the company executes a multi-year cost restructuring program.


Analysis · HUM · Finance

Humana's second quarter reveals a company in aggressive growth mode. Individual Medicare Advantage membership jumped 23% and stand-alone PDP membership surged 63% year-over-year, propelling total revenues up 26%. That expansion came at a cost: the consolidated benefit ratio rose to 91.1% from 89.7% a year ago, pressured by the onboarding of new members who typically incur higher medical costs and a sharp drop in favorable prior-year reserve development ($53M vs $161M). The company also absorbed $56M in restructuring charges tied to its multi-year transformation program. On the balance sheet, cash swelled to $6.9B following a $1B junior subordinated debt issuance and strong operating cash flow of $3.2B, providing ample liquidity for the $908M MaxHealth acquisition and ongoing share buybacks. The affirmed full-year adjusted EPS guidance of at least $9 — already above consensus — signals management confidence, but the rising benefit ratio and reliance on membership growth to offset Star Ratings headwinds are the key tension points investors will debate.

At the time of this filing, HUM was trading at $360.92 on NYSE in the Finance sector, with a market capitalization of approximately $43.3B. The 52-week trading range was $163.11 to $428.88. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HUM - Latest Insights

HUM
Jul 29, 2026, 1:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $362.82
Real-time Price: $360.92 info
Change: -$1.90 (-0.52%) info
Market Cap: $43.333B info
HUM
Jul 29, 2026, 10:17 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $358.92
Real-time Price: $360.92 info
Change: +$2.00 (+0.56%) info
Market Cap: $43.333B info
HUM
Jul 29, 2026, 6:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $354.00
Real-time Price: $360.92 info
Change: +$6.92 (+2%) info
Market Cap: $43.333B info
HUM
Jul 29, 2026, 6:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $372.00
Real-time Price: $360.92 info
Change: -$11.08 (-3%) info
Market Cap: $43.333B info
HUM
Jun 17, 2026, 9:18 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $369.49
Real-time Price: $360.92 info
Change: -$8.57 (-2%) info
Market Cap: $43.333B info